

**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse), 31.12.2017**

**Current report No. 1  
Dated 6 January 2017**

**NOTIFICATION**

2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab – Achieve – is undertaking a merger with another strong player in the development and registration of innovative medicines – Oncogenex, a publicly traded company on NASDAQ (<http://in.reuters.com/article/idINFWN1EV0QP>). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017.

Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.

**Current report No. 2  
Dated 9 January 2017**

**NOTIFICATION**

Sopharma AD hereby notifies that the revenues from sales for 2016 decrease with 5% compared to 2015, including 2% decrease in domestic sales mainly due to the overall market price erosion (for the same period the company has a 7% increase in sales in packages) and a 6% decrease in export sales.

“In the past few months we see some signs for economic and political stabilization in Russia, which give us certain security for the results of 2017. We are optimistic for the trend of recovery of the sales in the Ukraine. After the restructuring of our export activities our local teams work systematically for the increase of the results on a number of markets like Poland, Belarus, Latvia, etc. We are very proud with the successful registrations of new products which we are yet to develop. An excellent example is Tuspan – the coughing syrup, which will be available on a number of European markets even this year in case of successful and timely procedures. This year started with a long-awaited news concerning our project of registration of our product Tabex in the USA. In case a restructuring takes place between Achieve and Oncogenex (our remaining shares in the capital of Extab will be transformed in shares in Achieve in case of such restructuring) there will be two advantages for us: first, the new joint team of the two companies will have a much bigger chance of a successful registration of Tabex and second, “Sopharma” AD will become a shareholder in a public company traded on NASDAQ.”, says Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors, “Sopharma” AD.

**Current report No. 3**  
**Dated 30 January 2017**

Preliminary individual financial Statements for the period ending 31.12.2016.

**Current report No. 4**  
**Dated 2 February 2017**

**NOTIFICATION**

Sopharma AD announces that on 31 January, 2017 in accordance with art. 262e and the following from the Commercial Code Medica AD and Sopharma AD signed a contract for transformation through merger of Medica AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.9486, meaning that one share of Medica AD will be exchanged for 0.9486 shares of Sopharma AD. The companies have hired the services of certified appraisers whose report is a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the deputy Chairman “Investment Supervision” has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

**Current report No. 5**  
**Dated 3 February 2017**

**NOTIFICATION**

For the first month of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% decrease of domestic sales and 4% decrease of export sales.

**Current report No. 6**  
**Dated 13 February 2017**

**NOTIFICATION**

Sopharma AD (the “Company”) notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

**Current report No. 7**  
**Dated 27 February 2017**

### **NOTIFICATION**

Sopharma AD announces that the Competition Council of The Republic of Moldova allows the acquisition of over 51% of RAP Pharma International SRL by Sopharma AD.

**Current report No. 8**  
**Dated 1 March 2017**

Preliminary consolidated financial statements for the period ending 31 December 2016.

**Current report No. 9**  
**Dated 7 March 2017**

### **NOTIFICATION**

For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.

“We are very pleased with the results on the Russian market from the beginning of this year and the trend is strengthening in February reaching 40% increase in export sales.

We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more about the cooperation of Achieve with NIH here: [www.oncogenex.com](http://www.oncogenex.com).

The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.”, says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.

**Current report No. 10**  
**Dated 9 March 2017**

### **NOTIFICATION**

Sopharma AD announces that Sopharma AD received a final prohibition from the Bulgarian Financial Supervision Commission (FSC) to extend a tender offering to the shareholders of Unipharm AD. Sopharma AD is preparing a new tender offering which reflects the comments of the FSC.

**Current report No. 11**  
**Dated 17 March 2017**

Notification for Extraordinary General Meeting of shareholders of Sopharma AD

**Current report No. 12**  
**Dated 21 March 2017**

### **NOTIFICATION**

Sopharma AD (the "Company") notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.8831 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

**Current report No. 13**  
**Dated 31 March 2017**

Annual audited individual financial statements for the period ending 31 December 2016.

**Current report No. 14**  
**Dated 4 April 2017**

### **NOTIFICATION**

For the first quarter of this year, revenues from sales increased by 12% compared to the same period of 2016, including 4% decrease of domestic sales and 24% increase of export sales.

"Sales on the Russian market in March reassert the uptrend since the beginning of the year and are a real indicator of improving the economic situation. At present, our forecast are that export sales will grow also over the next few months.", said Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD.

**Current report No. 15**  
**Dated 6 April 2017**

### **NOTIFICATION**

Sopharma AD (the "Company") hereby notifies that on 5 April 2017 Sopharma AD received a decision from the Commission for Protection of Competition that the acquisition of shares of the capital of Doverie Obedinen Holding AD is not subject to preliminary notification under art. 24, para 2 from the Law on Competition at this stage.

Sopharma AD will undertake the respective actions once it reaches the thresholds requiring a tender offering to the remaining shareholders of Doverie Obedinen Holding AD.

**Current report No. 16**  
**Dated 18 April 2017**

### **NOTIFICATION**

Sopharma AD notifies that after receiving a permission from the Moldova Competition Commission, Sopharma AD acquired 51% of the Moldova pharmaceutical distributor RAP Pharma International.

RAP PHARMA INTERNATIONAL (RAP) was established in 2004 and in 2014 started its activities in the pharmaceutical sector after receiving a license for pharmaceutical wholesaling and distribution. Currently the company owns 10 pharmacies and is the most intensively developing company in the Republic of Moldova. The revenues of the company for 2016 increased with almost 40% to 3 million EUR. The company has 79 employees and is one of the 7 distributors in Moldova owning a pharmacies network. The retail market in Moldova for 2016 according to Pharmexpert is about 100 million EUR (a precise statistics is not available). Currently the company is a distributor of the products of Sopharma AD, Medica AD, Momina krepost AD, STADA, GRINDEX - Baltics, POLPHARMA, LEKPHARM - Belarus, FARMA PRIM - Moldova, FLUMED FARM - Moldova, BALKAN PHARMACEUTICALS - Moldova etc.. Since 2016 RAP Pharma is added in the list of companies supplying medicinal products to the State Hospitals in the Republic of Moldova through a centralized tender.

**Current report No. 17**  
**Dated 20 April 2017**

### **NOTIFICATION**

Sopharma AD (the "Company") hereby notifies all shareholders of the Company, that the Extraordinary General Meeting, convened by the Board of Directors for 24 April 2017 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. **The registration begins at 9:30.**

All shareholders of the company are invited to participate at the General Meeting in person or by proxy.

**As a prerequisite for the technical provisioning of the Extraordinary General Meeting of Shareholders, copies of all letters of attorney must be presented to the Company on paper or electronically at [mdnedkova@sopharma.bg](mailto:mdnedkova@sopharma.bg) by the end of the workday preceding the date of the AGM, namely 5 p.m. on 21 April 2017.**

We would like to thank all shareholders for their understanding and cooperation.

**Current report No. 18**  
**Dated 25 April 2017**

Minutes of the Extraordinary General Meeting of Shareholders of Sopharma AD.

**Current report No. 19**

**Dated 26 April 2017**

## **NOTIFICATION**

Sopharma AD (the “Company”) notifies that on 25 April 2017 the Financial Supervision Commission approved the Contract for transformation through merger and the additional annex to it, signed on 31 January 2017 between Sopharma AD, hereinafter referred to as "Acquirer" and Medica AD, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the reports of the appointed examiners of the participants in the transformation under art. 262M of the CA from 13 October 2014.

As a result of the merger, all shareholders of the Acquiree Medica AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.8813 shares of the capital of Sopharma AD.

**Current report No. 20**

**Dated 26 April 2017**

Notification about the proxy voting on the Extraordinary General Meeting of Shareholders of Sopharma AD.

**Current report No. 21**

**Dated 28 April 2017**

Individual Financial Statements as at 31 March 2017.

**Current report No. 22**

**Dated 28 April 2017**

Annual Audited Consolidated Financial Statements as at 31 December 2017.

**Current report No. 23**

**Dated 28 April 2017**

Notification for Annual General Meeting of Shareholders.

**Current report No. 24**

**Dated 3 May 2017**

## **NOTIFICATION**

Dear Shareholders,

The invitation for the Annual General Meeting of shareholders of Sopharma AD convened for 2 June, 2017 published in x3news, investor.bg and the website of the company [www.sopharmagroup.bg](http://www.sopharmagroup.bg) contains a technical mistake concerning the second date for the AGM, which is announced in case of lack of quorum on 2 June 2017:

In the first paragraph of the invitation the listed second date is 16 July 2017 and in the last paragraph the listed second date is 16 June 2017.

**We would hereby like to advise all shareholders that the correct second date under the conditions of art. 227, para 3 of the Commercial code for the Annual General Meeting of shareholders of Sopharma AD is 16 June 2017.**

**Current report No. 25  
Dated 3 May 2017**

#### **NOTIFICATION**

For the first four months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% increase of domestic sales and 18% increase of export sales.

**Current report No. 26  
Dated 5 May 2017**

#### **NOTIFICATION**

Sopharma AD notifies that regarding listing of additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD, scheduled for 02.06.2017, we present an updated invitation. Materials related to the new issues are published together with the other materials for the meeting on 02.06.2017.

**Current report No. 27  
Dated 30 May 2017**

Consolidated Financial Statements as at 31 March 2017.

**Current report No. 28  
Dated 2 June 2017**

#### **NOTIFICATION**

Sopharma AD hereby notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 2th, 2017 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.10 BGN /ten stotinki/ per share with dividend right.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken.

After the exact amount of the dividend has been determined, based on a list of shareholders, provided. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved.

**Current report No. 29**  
**Dated 5 June 2017**

#### **NOTIFICATION**

For the first five months of this year, revenues from sales increased by 15% compared to the same period of 2016, including 2% increase of domestic sales and 25% increase of export sales.

**Current report No. 30**  
**Dated 5 June 2017**

Minutes of the Annual General Meeting of Shareholders of Sopharma AD.

**Current report No. 31**  
**Dated 07 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:



<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2017	Buy	7 500	3.9810
01.06.2017	Buy	7 000	3.9810
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	7 000	3.9800
01.06.2017	Buy	900	4.0300
01.06.2017	Buy	500	4.0480
01.06.2017	Buy	500	4.0480
01.06.2017	Buy	500	4.0490
01.06.2017	Buy	500	4.0490
01.06.2017	Buy	50	4.0410
01.06.2017	Buy	100	4.0410

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 32**  
**Dated 8 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	125	4.3680
05.06.2017	Buy	80	4.3690
05.06.2017	Buy	500	4.3700
05.06.2017	Buy	2 420	4.3750
05.06.2017	Buy	850	4.3650
05.06.2017	Buy	850	4.3650
05.06.2017	Buy	850	4.3650

05.06.2017	Buy	450	4.3650
05.06.2017	Buy	3 000	4.3200
05.06.2017	Buy	3 000	4.3200
05.06.2017	Buy	150	4.3200
05.06.2017	Buy	850	4.3200
05.06.2017	Buy	200	4.3020
05.06.2017	Buy	300	4.3020
05.06.2017	Buy	3 000	4.3000
05.06.2017	Buy	1 000	4.2990
05.06.2017	Buy	2 000	4.3000
05.06.2017	Buy	1 750	4.3000
05.06.2017	Buy	650	4.3000
05.06.2017	Buy	1 000	4.3000
05.06.2017	Buy	500	4.3000
05.06.2017	Buy	500	4.3000
05.06.2017	Buy	50	4.3000
05.06.2017	Buy	1 000	4.2700
05.06.2017	Buy	2 000	4.2600
05.06.2017	Buy	254	4.2800
05.06.2017	Buy	137	4.2500
05.06.2017	Buy	200	4.2800
05.06.2017	Buy	4	4.2800
05.06.2017	Buy	50	4.2400
05.06.2017	Buy	54	4.2800
07.06.2017	Buy	1 000	4.3200
07.06.2017	Buy	201	4.3300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 33**  
**Dated 8 June 2017**

Notification about the proxy voting on the Annual General Meeting of Shareholders of Sopharma AD.

**Current report No. 34**  
**Dated 8 June 2017**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that on 7 June 2017 the Company received a notification for the acquisition of 503 000 shares, representing 0.37% of its capital, by “Donev investments holding” AD. After the transaction, the share of “Donev investments holding” AD in the capital of Sopharma AD reached 25.15%.

**Current report No. 35**

**Dated 8 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2017	Buy	765	4.3000
05.06.2017	Buy	150	4.3000
05.06.2017	Buy	85	4.3000
05.06.2017	Buy	1 000	4.2810
05.06.2017	Buy	100	4.2700
07.06.2017	Buy	500	4.2950

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 36**

**Dated 9 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.06.2017	Buy	2000	4.269
06.06.2017	Buy	1 850	4.3
06.06.2017	Buy	150	4.3
06.06.2017	Buy	1 000	4.3

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 37**

**Dated 12 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.06.2017	Buy	100	4.3000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 38**

**Dated 12 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.06.2017	Buy	10	4.302

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 39**

**Dated 12 June 2017**

## NOTIFICATION

We would like to notify that Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN **on 21 August 2017**.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

**Current report No. 40**  
**Dated 12 June 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
09.06.2017	Buy	191	4.2760
09.06.2017	Buy	59	4.2760
09.06.2017	Buy	100	4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 41**  
**Dated 12 June 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	4.3200	27
12.06.2017	Buy	4.3710	324
12.06.2017	Buy	4.3710	26
12.06.2017	Buy	4.4000	263

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 42**  
**Dated 14 June 2017**

#### **NOTIFICATION OF INSIDERS’ TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	300	4.3720
13.06.2017	Buy	700	4.41

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 43**  
**Dated 15 June 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
13.06.2017	Buy	800	4.4100
13.06.2017	Buy	22	4.4100
13.06.2017	Buy	178	4.4100
13.06.2017	Buy	200	4.3900
13.06.2017	Buy	350	4.3900
13.06.2017	Buy	250	4.3900
14.06.2017	Buy	50	4.4000
14.06.2017	Buy	50	4.4000
14.06.2017	Buy	100	4.4000
14.06.2017	Buy	700	4.4000
14.06.2017	Buy	150	4.4000
14.06.2017	Buy	650	4.4000
14.06.2017	Buy	57	4.3800
14.06.2017	Buy	23	4.3700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 44**  
**Dated 15 June 2017**

## NOTIFICATION

We are pleased to announce that the next step in the process of merging Achieve Lifesciences and Oncogenex has been completed with the approval of the merger by the US SEC. OncoGenex will hold a special shareholder meeting on 1 August 2017 to vote the merger. Shortly after the newly formed entity will trade on NASDAQ stock exchange under the ticker symbol ACHV.

**Current report No. 45**  
**Dated 15 June 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma” AD (the Company) announces that it was notified by „Elpharma” AD related to Ognian Ivanov Donev, that “Elpharma” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2017	Buy	500	4.3600
13.06.2017	Buy	100	4.3750
13.06.2017	Buy	70	4.3900
13.06.2017	Buy	30	4.3900
14.06.2017	Buy	100	4.4000
14.06.2017	Buy	250	4.4000
14.06.2017	Buy	120	4.3810

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 46**  
**Dated 16 June 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
15.06.2017	Buy	100	4.2890
15.06.2017	Buy	200	4.3100



The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 47**

**Dated 16 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.06.2017	Buy	100	4.37

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 48**

**Dated 21 June 2017**

### **NOTIFICATION**

On the grounds of Art. 157 of POSA in connection with Art. 154 of the Public Offering of Securities Act and in connection with the expired deadline for acceptance of the tender offer submitted by Sopharma AD to the shareholders of Unipharm AD, we inform you about the results of the tender offering submitted by Sopharma AD for the purchase of the shares of the other shareholders of Unipharm AD.

Company, object of the offer: Unipharm AD, with management address Sofia 1797, Studentski grad, zh.k. Darvenitsa, Trayko Stanoev Str.

Tender offeror: Sopharma AD, with address: Sofia, Nadezhda district, 16, Iliensko shose Str.

Authorized investment intermediary: Elana Trading AD, with management address: Sofia, Sredets, 4, Kuzman Shapkarev Str., and license issued by FSC for carrying out activity as an investment intermediary on the basis of Decision No. 171 -IP / 08.03.2006

Price offered per share: BGN 4.35 (four leva thirty-five stotinki) Number of persons accepted the tender offer: 65 Shareholder with total number of shares: 1 125 021, representing 18.75% of the capital of Unipharm AD.

As a result of the tender offer and after the conclusion of the transactions with the shareholders that have accepted it, Sopharma AD will directly own 96.63% of the shares of Unipharm AD. Sopharma AD has the right, within three months from the closing date of the tender offer, to submit, after obtaining the approval of the FSC, an offer for the purchase of the shares of the remaining shareholders of Unipharm AD on the grounds of Art. 157a of POSA. In addition, according to the provisions of Art. 157b of the POSA, each shareholder is entitled to require from Sopharma AD to redeem his/her shares until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the proposal under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the tender offering of BGN 4.35 per share.

The results of the tender offering were published by the tender offeror in the newspapers "Capital Daily" and "Sega" as of 21.06.2017.

**Current report No. 49**  
**Dated 21 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
16.06.2017	Buy	100	4.3150
16.06.2017	Buy	60	4.3160
16.06.2017	Buy	40	4.3160
16.06.2017	Buy	200	4.3000
16.06.2017	Buy	120	4.3200
16.06.2017	Buy	60	4.2950
16.06.2017	Buy	200	4.3190
16.06.2017	Buy	100	4.3400
20.06.2017	Buy	500	4.4200
20.06.2017	Buy	100	4.4580

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 50**

**Dated 26 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
22.06.2017	Buy	150	4.4330
22.06.2017	Buy	600	4.4000
22.06.2017	Buy	490	4.4000
22.06.2017	Buy	400	4.4000
22.06.2017	Buy	1 000	4.4000
22.06.2017	Buy	320	4.4000
22.06.2017	Buy	500	4.4000
22.06.2017	Buy	180	4.4000
22.06.2017	Buy	795	4.4000
22.06.2017	Buy	205	4.4000
22.06.2017	Buy	1 000	4.4000
22.06.2017	Buy	1 000	4.4000
23.06.2017	Buy	220	4.3990
23.06.2017	Buy	300	4.4000
23.06.2017	Buy	200	4.4100

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 51**

**Dated 28 June 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
26.6.2017 10:22	Buy	2 000	4.4000
26.6.2017 10:28	Buy	280	4.4000
26.6.2017 12:27	Buy	200	4.4000
26.6.2017 13:20	Buy	300	4.4000
26.6.2017 13:30	Buy	500	4.4000
26.6.2017 13:31	Buy	124	4.4000
26.6.2017 13:50	Buy	376	4.4000
26.6.2017 15:23	Buy	300	4.4400
26.6.2017 16:24	Buy	190	4.4400
26.6.2017 16:24	Buy	363	4.4470
26.6.2017 16:42	Buy	100	4.4470
26.6.2017 16:42	Buy	47	4.4470
26.6.2017 17:00	Buy	100	4.4480
26.6.2017 17:00	Buy	300	4.4480
27.6.2017 10:14	Buy	100	4.4500
27.6.2017 10:22	Buy	4 200	4.4500
27.6.2017 12:37	Buy	100	4.4920
27.6.2017 15:56	Buy	250	4.4650
27.6.2017 15:58	Buy	250	4.4890

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 52**  
**Dated 30 June 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
28.6.2017 10:13	Buy	200	4.4650
28.6.2017 10:14	Buy	1 800	4.4650
28.6.2017 10:22	Buy	234	4.4990
28.6.2017 10:22	Buy	69	4.4990
28.6.2017 10:22	Buy	470	4.4990
28.6.2017 10:22	Buy	427	4.5000
28.6.2017 10:22	Buy	1 000	4.5000
28.6.2017 10:36	Buy	250	4.5290
28.6.2017 10:36	Buy	750	4.5300
28.6.2017 10:42	Buy	1 000	4.5400
28.6.2017 10:57	Buy	624	4.5500
28.6.2017 10:57	Buy	376	4.5500
29.6.2017 10:42	Buy	400	4.5500
29.6.2017	Buy	1 000	4.5310

10:46			
30.6.2017 10:44	Buy	1 000	4.5000
30.6.2017 10:44	Buy	848	4.5000
30.6.2017 10:49	Buy	152	4.5000
30.6.2017 10:55	Buy	600	4.5000
30.6.2017 15:31	Buy	2 000	4.5000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 53**  
**Dated 4 July 2017**

#### **NOTIFICATION**

Sopharma AD notifies that for June 2017 the Company recorded an increase of sales revenues of 31% compared to the same month of 2016, including 2% decrease of domestic sales and 59% increase of export sales.

For the first six months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.

**Current report No.54**  
**Dated 17 July 2017**

#### **NOTIFICATION**

We would like to notify that in interest of its shareholders Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN earlier than planned **on 24 July 2017**.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

**Current report No. 55**  
**Dated 21 July 2017**

### **NOTIFICATION**

We would like to notify that “Sopharma” AD acquired 75% from the capital of the successful start-up for development and registration of food additives “Aromania” ([www.arolife.bg](http://www.arolife.bg)).

For the nearly two years since its establishment “Aromania” has more than 20 registered products and for 12 of them the company either has or has filed a different form of patent protection - trade mark, industrial design or useful model. Two of the products are leaders in their categories. For 2016 the revenues from sales of the company are 1,279 thousand BGN.

Sopharma will use this platform for a wider presence on the food additives market and to proudly enter the society of the “Bulgarian business angels”.

**Current report No. 56**

Individual financial statements as at 30 June 2017.

**Current report No.57**  
**Dated 31 July 2017**

### **NOTIFICATION**

Sopharma AD notifies that the stabilization of the economic environment on our main export markets and the optimization of the operations of Sopharma AD led to 73% increase of the operating profit from BGN 14 310 thousand for the first half of 2016 BGN 24 698 thousand for the first half of 2017 and of 50% increase of EBITDA from BGN 21 318 thousand for the first half of 2016 to BGN 32 048 thousand for the first half of 2017.

“Our efforts towards improving the way we operate, to further improve the synergy after the merger with Bulgarian Rose – Sevtopolis AD, to optimize or trade activities and to start new, interesting and profitable projects are reconfirmed in our financial results. We also appreciate the fact that factors outside of our control also improved leading to fast growth. We are proud that our subsidiary Sopharma Trading AD received a green light from to start larger projects in Serbia.”, comments Ognian Donev, PhD, Executive director and Chairman of the Board of directors of Sopharma AD.

**Current report No.58**  
**Dated 2 August 2017**

### **NOTIFICATION**

Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV).

The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advancing our development program," commented Rick Stewart, Chairman and CEO of Achieve Life Science.

<http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=1030091>

**Current report No. 59**  
**Dated 3 August 2017**

### NOTIFICATION

Sopharma AD notifies that on 2 August 2017 Sopharma AD acquired 1537 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

**Current report No. 60**  
**Dated 3 August 2017**

### NOTIFICATION

Sopharma AD notifies that for July 2017 the Company recorded an increase of sales revenues of 17% compared to the same month of 2016, including 2% increase of domestic sales and 25% increase of export sales.

For the first seven months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.

**Current report No. 61**  
**Dated 9 August 2017**

### NOTIFICATION



Sopharma AD notifies that the transformation through merger of Medika AD in Sopharma AD has been registered with the Commercial Register with number 20170808155501.

**Current report No. 62**

**Dated 15 August 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „ Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.06.2017	Buy	503000	3.98
06.06.2017	Sale	200	4.305
06.06.2017	Sale	100	4.310
06.06.2017	Sale	1200	4.302
07.06.2017	Sale	1000	4.32
07.06.2017	Sale	1000	4.32
07.06.2017	Sale	500	4.34
07.06.2017	Sale	10	4.34
07.06.2017	Sale	290	4.34
07.06.2017	Sale	218	4.35
07.06.2017	Sale	282	4.35
07.06.2017	Sale	500	4.355
07.06.2017	Sale	1000	4.33
07.06.2017	Sale	1000	4.33
08.06.2017	Sale	1500	4.302
08.06.2017	Sale	290	4.302
08.06.2017	Sale	30	4.302
08.06.2017	Sale	1000	4.302
08.06.2017	Sale	1000	4.302
08.06.2017	Sale	1000	4.302
08.06.2017	Sale	1000	4.302
09.06.2017	Sale	325	4.29
09.06.2017	Sale	100	4.29
09.06.2017	Sale	123	4.29
09.06.2017	Sale	277	4.29
12.06.2017	Sale	45	4.35
12.06.2017	Sale	205	4.35
12.06.2017	Sale	159	4.40
12.06.2017	Sale	340	4.40
12.06.2017	Sale	1	4.40
13.06.2017	Sale	150	4.395
15.06.2017	Buy	300	4.25
16.06.2017	Sale	245	4.315

16.06.2017	Sale	100	4.315
16.06.2017	Sale	155	4.315
16.06.2017	Sale	245	4.315
16.06.2017	Sale	100	4.315
16.06.2017	Sale	155	4.315
16.06.2017	Sale	100	4.340
16.06.2017	Sale	100	4.340
30.06.2017	Buy	100	4.552

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 63**

**Dated 29 August 2017**

Consolidated financial statements as at 30 June 2017.

**Current report No. 64**

**Dated 29 August 2017**

Due to a technical mistake we publish a revised management report.

**Current report No. 65**

**Dated 5 September 2017**

**NOTIFICATION**

Sopharma AD notifies that for August 2017 the Company recorded an increase of sales revenues of 12% compared to the same month of 2016, including 12% increase of domestic sales and 12% increase of export sales.

For the first eight months of this year, revenues from sales increased by 17% compared to the same period of 2016, including 3% increase of domestic sales and a 27% increase of export sales.

**Current report No. 66**

**Dated 5 September 2017**

**NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.09.2017	Buy	500	4.6050
01.09.2017	Buy	5 000	4.6000
01.09.2017	Buy	2 320	4.6000
01.09.2017	Buy	85	4.6500
01.09.2017	Buy	1 915	4.6500
01.09.2017	Buy	2 680	4.6000
01.09.2017	Buy	100	4.7450
01.09.2017	Buy	170	4.7490
01.09.2017	Buy	140	4.7500
01.09.2017	Buy	185	4.7940
01.09.2017	Buy	100	4.7950
01.09.2017	Buy	700	4.7950
01.09.2017	Buy	165	4.7970
01.09.2017	Buy	1 000	4.7980
01.09.2017	Buy	300	4.8000
01.09.2017	Buy	2 961	4.8000
01.09.2017	Buy	574	4.8000
01.09.2017	Buy	160	4.7990
01.09.2017	Buy	1	4.8000
01.09.2017	Buy	1 839	4.8000
01.09.2017	Buy	1 000	4.8050
01.09.2017	Buy	85	4.8000
01.09.2017	Buy	915	4.8000
01.09.2017	Buy	190	4.7500
01.09.2017	Buy	20	4.7400
01.09.2017	Buy	495	4.7400
01.09.2017	Buy	485	4.7400
01.09.2017	Buy	100	4.7000
01.09.2017	Buy	250	4.7190
01.09.2017	Buy	170	4.7440
01.09.2017	Buy	500	4.7450
01.09.2017	Buy	340	4.7790
01.09.2017	Buy	233	4.7800
01.09.2017	Buy	170	4.7870
01.09.2017	Buy	180	4.7890
01.09.2017	Buy	3 000	4.7900
01.09.2017	Buy	407	4.7900
01.09.2017	Buy	3 000	4.7200
01.09.2017	Buy	500	4.7900
01.09.2017	Buy	300	4.7880
01.09.2017	Buy	25	4.7880

01.09.2017	Buy	200	4.7890
01.09.2017	Buy	790	4.7890
01.09.2017	Buy	185	4.7890
01.09.2017	Buy	1 000	4.7500
04.09.2017	Buy	1 000	4.7700
04.09.2017	Buy	2 000	4.7700
04.09.2017	Buy	288	4.7600
04.09.2017	Buy	112	4.7600
04.09.2017	Buy	300	4.7400
04.09.2017	Buy	5 000	4.6500
04.09.2017	Buy	1 000	4.6500
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	500	4.6850
05.09.2017	Buy	434	4.6850
05.09.2017	Buy	500	4.6850
05.09.2017	Buy	800	4.6650
05.09.2017	Buy	200	4.6650
05.09.2017	Buy	700	4.6850
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	100	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	300	4.6890
05.09.2017	Buy	200	4.6890
05.09.2017	Buy	31	4.6890
05.09.2017	Buy	269	4.6890
05.09.2017	Buy	400	4.6900
05.09.2017	Buy	700	4.6900
05.09.2017	Buy	585	4.6900
05.09.2017	Buy	40	4.6900
05.09.2017	Buy	271	4.6800
05.09.2017	Buy	735	4.6800
05.09.2017	Buy	1 500	4.6700
05.09.2017	Buy	2 000	4.6650
05.09.2017	Buy	964	4.6400
05.09.2017	Buy	1 000	4.6590
05.09.2017	Buy	500	4.7000
05.09.2017	Buy	230	4.7000
05.09.2017	Buy	770	4.7000
05.09.2017	Buy	66	4.6500
05.09.2017	Buy	270	4.7000
05.09.2017	Buy	230	4.7000
05.09.2017	Buy	3 000	4.7000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 67**  
**Dated 5 September 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.09.2017	Buy	200	4.7000
01.09.2017	Buy	100	4.7000
01.09.2017	Buy	500	4.7450
04.09.2017	Buy	42	4.7600
04.09.2017	Buy	100	4.7610
04.09.2017	Buy	70	4.7610
04.09.2017	Buy	288	4.7600
04.09.2017	Buy	1 000	4.7700
04.09.2017	Buy	1 000	4.7650
04.09.2017	Buy	400	4.7570
04.09.2017	Buy	112	4.7600
04.09.2017	Buy	2 000	4.7450

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 68**  
**Dated 7 September 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
01.09.2017	Buy	2000	4.600
01.09.2017	Buy	2000	4.700
01.09.2017	Buy	2000	4.705
01.09.2017	Buy	350	4.720
01.09.2017	Buy	515	4.740
01.09.2017	Buy	485	4.740
01.09.2017	Buy	15	4.720
01.09.2017	Buy	1 000	4.690
01.09.2017	Buy	500	4.690
01.09.2017	Buy	200	4.700
01.09.2017	Buy	500	4.770
01.09.2017	Buy	500	4.790
04.09.2017	Buy	1000	4.77
04.09.2017	Buy	1000	4.765
04.09.2017	Buy	2000	4.745
04.09.2017	Buy	1000	4.72
05.09.2017	Buy	20	4.640
05.09.2017	Buy	700	4.650
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	1000	4.660
05.09.2017	Buy	957	4.660
05.09.2017	Buy	43	4.660
05.09.2017	Buy	612	4.660
05.09.2017	Buy	20	4.660
05.09.2017	Buy	100	4.684
05.09.2017	Buy	2 368	4.660
05.09.2017	Buy	1 000	4.640

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 69**  
**Dated 8 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
7.09.2017	Buy	300	4.6950
7.09.2017	Buy	100	4.6990
7.09.2017	Buy	500	4.7000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 70**  
**Dated 11 September 2017**

#### **NOTIFICATION**

Sopharma AD notifies that on 8 September 2017 Sopharma AD acquired 111 066 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

**Current report No. 71**  
**Dated 11 September 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.09.2017	Sale	1 000	4.5960
08.09.2017	Sale	200	4.5900
08.09.2017	Sale	100	4.5900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 72**  
**Dated 11 September 2017**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev*, *Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
8.09.2017	Buy	500	4.6150
8.09.2017	Buy	500	4.6120
8.09.2017	Buy	2 000	4.6050
8.09.2017	Buy	2 615	4.6020
8.09.2017	Buy	385	4.6020
8.09.2017	Buy	200	4.5900
8.09.2017	Buy	200	4.5800



The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 73**  
**Dated 11 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.09.2017	Buy	200	4.6450
08.09.2017	Buy	1 000	4.6050

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 75**  
**Dated 12 September 2017**

#### **ACQUISITION OF OWN SHARES**

*SOPHARMA AD hereby informs that on 11 September 2017 the Company bought 10 000 own shares representing 0.0074% of the share capital of the Company, at a total value of 45 125.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.51 BGN.*

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 255 102, representing 3.90 % of the share capital of the Company.

**Current report No. 75**  
**Dated 12 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev*, *Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.09.2017	Buy	471	4.5500
11.09.2017	Buy	29	4.5500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 76**  
**Dated 12 September 2017**

#### **NOTIFICATION OF INSIDERS’ TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev*, *Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.09.2017	Buy	200	4.5800
11.09.2017	Buy	200	4.5700
11.09.2017	Buy	1 000	4.5150
11.09.2017	Buy	570	4.5150
11.09.2017	Buy	200	4.5200

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No.77**  
**Dated 12 September 2017**

#### **NOTIFICATION**

The Board of Directors of Sopharma notifies that it took a decision to initiate a procedure for merging Unipharm AD, VAT number 831537465 based in the city of Sofia on 3, “Trayko Stanoev” Str. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130, based on 5, Lachezar Stanchev Str. for a consultant in relation to the merger.

**Current report No. 78**  
**Dated 14 September 2017**

### **NOTIFICATION**

Sopharma AD announces that on 14 September, 2017 in accordance with art. 262e and the following from the Commercial Code Unipharm AD and Sopharma AD signed a contract for transformation through merger of Unipharm AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.891512, meaning that one share of Unipharm AD will be exchanged for 0.891512 shares of Sopharma AD. The companies have hired the services of certified appraisers whose reports are a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the responsible Deputy Chairman of the FSC has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

**Current report No. 79**  
**Dated 15 September 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
07.09.2017	Buy	3000	4.68
07.09.2017	Buy	1000	4.68
07.09.2017	Buy	1900	4.68
07.09.2017	Buy	100	4.68
08.09.2017	Buy	500	4.607
08.09.2017	Buy	1000	4.596
11.09.2017	Buy	1000	4.565

11.09.2017	Buy	121	4.550
11.09.2017	Buy	379	4.550
12.09.2017	Buy	2000	4.501
13.09.2017	Buy	1000	4.461
13.09.2017	Buy	5000	4.460
13.09.2017	Buy	5000	4.370

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No.80**  
**Dated 15 September 2017**

#### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.09.2017	Buy	3 000	4.5010
13.09.2017	Buy	200	4.4000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 81**  
**Dated 15 September 2017**

#### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.09.2017	Buy	2 000	4.5000
12.09.2017	Buy	120	4.4800
12.09.2017	Buy	100	4.4800
12.09.2017	Buy	1 780	4.4800
13.09.2017	Buy	1 000	4.4600
13.09.2017	Buy	1 000	4.4550
13.09.2017	Buy	2 000	4.3700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 82**  
**Dated 15 September 2017**

#### **ACQUISITION OF OWN SHARES**

*SOPHARMA AD hereby informs that from 12 September 2017 up to and including 14 September 2017 the Company bought 50 000 own shares representing 0.037% of the share capital of the Company, at a total value of 222 085.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.44 BGN.*

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 303 022, representing 3.93 % of the share capital of the Company.

**Current report No. 83**  
**Dated 15 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.09.2017	Buy	1 000	4.5000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No 84/ 2017**  
**Dated 18 September 2017**

*SOPHARMA AD hereby informs that 15 September 2017 the Company bought 15 695 own shares representing 0.011% of the share capital of the Company, at a total value of 67 954.41 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.*

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 318 717, representing 3.95 % of the share capital of the Company.

**Current report No. 85**  
**Dated 19 September 2017**

**ACQUISITION OF OWN SHARES**

*SOPHARMA AD hereby informs that from 15 September 2017 up to and including 18 September 2017 the Company bought 10 600 own shares representing 0.0079% of the share capital of the Company, at a total value of 44 878.01 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.*

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 329 317, representing 3.95 % of the share capital of the Company.

**Current report No. 86**  
**Dated 19 September 2017**

**NOTIFICATION**

Sopharma AD notifies that on 18 September 2017 Sopharma AD acquired 345 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the

offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

**Current report No. 87**  
**Dated 19 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.09.2017	Buy	151	4.410
15.09.2017	Buy	200	4.380
15.09.2017	Buy	500	4.330
18.09.2017	Buy	3 000	4.280
18.09.2017	Buy	1 312	4.230
18.09.2017	Buy	180	4.230
18.09.2017	Buy	1 000	4.230
18.09.2017	Buy	1 508	4.230
18.09.2017	Buy	382	4.220
18.09.2017	Buy	5 218	4.220
18.09.2017	Buy	2 000	4.210
18.09.2017	Buy	1 272	4.200
18.09.2017	Buy	4 328	4.200

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 88**  
**Dated 19 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
18.09.2017	Buy	408	4.2100
18.09.2017	Buy	4 000	4.2100
18.09.2017	Buy	592	4.2100
18.09.2017	Buy	5 533	4.2000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 89**  
**Dated 20 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
19.09.2017	Buy	1 000	4.1400
19.09.2017	Buy	695	4.1400
19.09.2017	Buy	305	4.1400
19.09.2017	Buy	200	4.1300
19.09.2017	Sale	600	4.2450

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 90**  
**Dated 20 September 2017**

#### **NOTIFICATION**

Sopharma AD notifies that from 18 September 2017 up to and including 19 September 2017 Sopharma AD acquired 12 927 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 157b from the LOPS.



The term under art. 157b expired on 19 September 2017.

**Current report No. 91**  
**Dated 21 September 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
20.09.2017	Sale	50	4.3000
20.09.2017	Sale	50	4.3000
20.09.2017	Sale	100	4.2910
20.09.2017	Sale	104	4.3010
20.09.2017	Sale	150	4.3100
20.09.2017	Sale	150	4.3100
20.09.2017	Sale	1 000	4.3300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 92**  
**Dated 21 September 2017**

### **ACQUISITION OF OWN SHARES**

*SOPHARMA AD hereby informs* that from 20 September 2017 the Company bought 5650 own shares representing 0.0042% of the share capital of the Company, at a total value of 24 441.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 153 126, representing 3.82 % of the share capital of the Company.

**Current report No. 93**  
**Dated 21 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
20.09.2017	Sale	4.290	150
20.09.2017	Sale	4.290	100
20.09.2017	Sale	4.330	500
20.09.2017	Sale	4.301	150
20.09.2017	Sale	4.301	1 850
20.09.2017	Sale	4.301	750
20.09.2017	Sale	4.330	500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 94**  
**Dated 25 September 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date and time(UTC) of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
21.09.2017	Sale	700	4.3100
21.09.2017	Sale	300	4.3100
21.09.2017	Sale	1 000	4.3600
21.09.2017	Sale	1 000	4.3600
21.09.2017	Sale	500	4.3600
21.09.2017	Sale	115	4.3450
21.09.2017	Sale	885	4.3450
21.09.2017	Sale	500	4.3010

21.09.2017	Sale	126	4.3000
21.09.2017	Sale	174	4.3000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 95**  
**Dated 25 September 2017**

### ACQUISITION OF OWN SHARES

*SOPHARMA AD hereby informs* that on 21 September 2017 the Company bought 6635 own shares representing 0.0049% of the share capital of the Company, at a total value of 28750.33.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 159 761, representing 3.83 % of the share capital of the Company.

**Current report No. 96**  
**Dated 27 September 2017**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
26.09.2017	Sale	850	4.4000
26.09.2017	Sale	111	4.4300
26.09.2017	Sale	26	4.4300
26.09.2017	Sale	363	4.4300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 97**  
**Dated 27 September 2017**

### **NOTIFICATION**

*Regarding: Notification from Sopharma AD under Art. 44n of ORDINANCE № 13 of 22.12.2003 for tender offering for the purchase and exchange of shares of Unipharm AD*

Sopharma AD notifies that in conjunction with the tender offering made on the grounds of Art. 149 para. 6 of the Public Offering of Securities Act and the right of the shareholders who have not accepted the offer under Art. 157b, we provide information for the fulfillment of the obligation of Sopharma AD under this Article:

1. The offeror has bought a total of 125 530 shares with voting right of Unipharm AD;
2. 17 shareholders have applied for share buy-back under the right given to them by Art. 157b of POSA.

**Current report No. 98**  
**Dated 28 September 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
27.09.2017	Buy	500	4.3900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No. 99**  
**Dated 29 September 2017**

### **ACQUISITION OF OWN SHARES**

*SOPHARMA AD hereby informs* that on 26 September 2017 the Company bought 1000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4400.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.4 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 160 761, representing 3.83 % of the share capital of the Company.

**Current report No 100/2017**  
**Dated 2 October 2017**

### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva*, person closely associated with *Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
28.09.2017	Sale	400	4.3900
28.09.2017	Sale	100	4.3900
28.09.2017	Sale	500	4.3900
28.09.2017	Sale	500	4.3900
28.09.2017	Sale	234	4.3900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No 101/2017**  
**Dated 4 October 2017**

Sopharma AD notifies that for September 2017 the Company recorded an increase of sales revenues of 8% compared to the same month of 2016, including 1% decrease of domestic sales and 11% increase of export sales.

For the first nine months of this year, revenues from sales increased by 16% compared to the same period of 2016, including 2% increase of domestic sales and a 25% increase of export sales. After the merger of Medica AD, from the beginning of the year the Company recorded an increase of sales revenues of 25%, including 29% increase of export sales and 19% increase of domestic sales.

**Current report No 102/2017**  
**Dated 5 October 2017**

We would like to notify that on **November 3 2017 (Friday)** Sopharma AD organizes an Annual Meeting with Investors, on which Sopharma AD and Sopharma Trading AD will present the main goals achieved and the new challenges. The meeting will take place in the Conference center of Sopharma Business Towers, Sofia. We kindly request that all interested parties notify us not later than **October 20 2017** by e-mail [irevents@sopharma.bg](mailto:irevents@sopharma.bg) or by telephone +3592 8134 319 in order to receive their registration forms. Places are limited.

**Current report No 103/2017**  
**Dated 30 October 2017**

Financial Statements for the third quarter of 2017.

**Current report No 104/2017**  
**Dated 3 November 2017**

Sopharma AD notifies that for October 2017 the Company recorded an increase of sales revenues of 7% compared to the same month of 2016, including 3% increase of domestic sales and 12% increase of export sales.

For the first ten months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 2% decrease of domestic sales and a 23% increase of export sales.

**Current report No 105/2017**  
**Dated 6 November 2017**

We would like to notify that an Annual meeting with the investors of Sopharma AD was held on 3 November 2017, which started at 2.30 pm and ended at 6.30 pm. The following announcement regarding the liability was made:

*"Please note that at the Annual Meeting with the Investors of SOPHARMA AD (" the Company ") can be made oral and written "forward looking statements" about future events, which are essentially uncertain because they do not concern only past or current facts. All such statements are also based on a number of assumptions, expectations, forecasts and preliminary data for future events, determined by factors beyond the control of SOPHARMA AD, which are therefore uncertain and should not be considered as a reliable indicator of future results . The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except as may be required by applicable law. The information and opinions set forth in this meeting are current as of the date of the meeting and are subject to change without prior notice. Neither the information disclosed at this meeting, nor any part of it, nor*

*the fact of its distribution, may serve as a ground upon which a party may invoke or in relation to which to sign a contract or to make an investment decision.*

*Sopharma AD is not responsible neither for decisions and actions taken based on the content of the information from this meeting nor for damages caused as a result of such actions and decisions.*

*The information, statements and opinions submitted at this meeting are for information purposes only and do not constitute a public offer under any applicable legislation or an offer for sale or solicitation for an offer for the purchase or subscribe of securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments. None of the securities referred to herein have been or will be, registered under the US Securities Act 1933 or any subsequent amendments, or under the securities laws of any state or other jurisdiction of the United States or in Australia, Canada or Japan or in any other country where such an offer or invitation would be illegal (the "other countries") and there will be no public offering of such securities in the United States. This information does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States or other countries.*

*Neither the Company, nor any member of the management of Sopharma AD, nor any of its representatives, directors or employees, accepts any liability whatsoever with connection with the information provided at this meeting or in relation to any loss from its use or from any reliance placed on it. "*

At the meeting, Sopharma AD, Sopharma Group and Sopharma Trading AD were introduced by short presentations about the financial results for the first nine months of 2017. During the discussion session, a number of questions were asked, as a result of which the companies provided explanations regarding the following main areas of their activity:

1. Capital Investments - Sopharma AD announced that currently have been made decisions for exploring the possibilities for construction of two production facilities - in Kazanlak - extraction power and in Sofia new lyophilic production.
2. The registration of the product TABEX in the USA - Mr. Donev announced that at this stage, details are still unknown, as the start of clinical tests will begin in 2018.
3. Optimization, improvement of the operating result - Mr. Donev replied that this is mainly due to the optimization of the processes in the Group and in the Company, which continue with the intentions of the merger of Unipharm AD, whose documents are subject of approval by the FSC. In addition, Mr. Donev mentioned the projects for renovation of "Momina krepost" AD with European funds, which will allow the company to be more competitive and to offer better products.
4. External Markets - The new, rapidly growing but small-scale markets like Vietnam and the improvement of the macroeconomic environment in Russia and Ukraine were mentioned.
5. Shareholder Structure - Mr. Donev commented that at a meeting with the management of Romfarm, that he was allowed to cite, it was shared that Rompharm had left their trusted management package and that they were not the initiators of the recent actions during the last few months, as well as that they did not intend to go below the price of 4.27 BGN.
6. Sopharma Group - Mr. Dimitrov commented on the state of the Serbian market, namely that its maturity determines the possibility of big growth, as it was in Bulgaria about 10 years ago. Sopharma Trading AD considers that Lekovit's post-acquisition phase is going very well and that the plans for the Group, while preserving the macroeconomic framework, are at least doubling sales revenue over the next three years.
7. Retail at Sopharma Trading AD - questions about the "SOpharmacy" chain and its development, Mr. Dimitrov replied that all pharmacies grow faster than the market.

**Current report No 106/2017**  
**Dated 16 November 2017**

We would like to notify that within the fourteenth meeting of the Vienna Economic Forum “Vienna future dialogue 2017” Ognian Donev PhD, Chairman of the Board of Directors and Executive Director of Sopharma AD received the Forum award for “Contribution to the economic development on national and regional level”.

In 2015 Mr. Donev was elected vice-president of the Vienna Economic Forum and on the November meeting this year he was invited to moderate the panel “Digital economy – expectations and reality”. Each year the Forum gathers guests from different areas – politicians, economists, business leaders etc.

**Current report No 107/2017**  
**Dated 16 November 2017**

We would like to notify that the company BRIZ, a subsidiary of Sopharma, operating on the markets of the Baltics and Belarus, which turned 26 this year, was awarded with the Paracelsusaward.

This award is presented every four years by the Association of Pharmacists of the Baltic States in the framework of the Congress of Pharmacists. For the award high-tech and progressive companies are nominated with high quality standards and innovative approach to work.

BRIZ received the award for innovations in the field of pharmacy, rapid development on the markets, as well as for merits in international cooperation.

**Current report No 108/2017**  
**Dated 29 November 2017**

Consolidated Financial Statements for the third quarter of 2017.

**Current report No 108/2017**  
**Dated 4 December 2017**

Sopharma AD notifies that for November 2017 the Company recorded an increase of sales revenues of 11% compared to the same month of 2016, including 11% increase of domestic sales and 12% increase of export sales.

For the first eleven months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% decrease of domestic sales and a 21% increase of export sales.

**Current report No 110/2017**  
**Dated 6 December 2017**

*SOPHARMA AD* hereby informs that from 1st to 5th December 2017 the Company bought 924 732 own shares representing 0.686% of the share capital of the Company, at a total value of 3 948 605.64 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.



The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 6 085 493, representing 4.51% of the share capital of the Company.

**Current report No111 /2017**

**Dated 6 December 2017**

Sopharma AD hereby informs that on 6 December 2017 the Company bought 3 061 292 own shares representing 2.271% of the share capital of the Company, at a total value of 13 071 716.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 146 785, representing 6.786% of the share capital of the Company. With these transactions Sopharma AD passed the threshold of 5% for the treasury shares.

**Current report No 113/2017**

**Dated 8 December 2017**

Sopharma AD hereby informs that on 7 December 2017 the Company bought 105 844 own shares representing 0.0785% of the share capital of the Company, at a total value of 451 979.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 882 629, representing 6.590% of the share capital of the Company.

**Current report No 114/2017**

**Dated 8 December 2017**

Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD.

The first notification concerns the sale of 6 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017.

The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017.

**Current report No 116**  
**Dated 8 December 2017**

**NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.12.2017	Buy	6000	4.27
05.12.2017	Buy	2000	4.27
06.12.2017	Buy	400 000	4.27
06.12.2017	Buy	6 000	4.27
06.12.2017	Buy	6 000	4.27
06.12.2017	Buy	2 000	4.27
06.12.2017	Buy	3 000	4.27
06.12.2017	Buy	567	4.27
07.12.2017	Buy	2000	4.27
07.12.2017	Buy	1000	4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No 117**  
**Dated 8 December 2017**

**NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by *Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors* that she, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.12.2017	Buy	7 000	4.2700
05.12.2017	Buy	6 500	4.2700
05.12.2017	Buy	6 500	4.2700

06.12.2017	Buy	600	4.2700
07.12.2017	Buy	200	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Current report No 118**  
**Dated 8 December 2017**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.12.2017	Buy	2 000	4.2700
06.12.2017	Buy	1 000	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 8 December 2017**  
**Current report No 119**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma" AD (the Company) announces that it was notified by „Donev Investments Holding" AD related to Ognian Ivanov Donev, that „Donev Investments Holding" AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.12.2017	Buy	3000	4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 December 2017**  
**Current report No 120**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
08.12.2017	Buy	2 000	4.2700
11.12.2017	Buy	3 000	4.2700
11.12.2017	Buy	2 000	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 12 December 2017**  
**Current report No 121**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.12.2017	Buy	3000	4.27
06.12.2017	Buy	4000	4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 14 December 2017**  
**Current report No 122**

Sopharma AD hereby informs that on 13 December 2017 the Company bought 6 251 own shares representing 0.0046% of the share capital of the Company, at a total value of 26 753.18 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 888 880, representing 6.59 % of the share capital of the Company.

**Dated 14 December 2017**

**Current report No 123**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
13.12.2017	Buy	165	4.2960
13.12.2017	Buy	5 000	4.2800
13.12.2017	Buy	835	4.2800

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 15 December 2017**

**Current report No 124**

Sopharma AD hereby informs that on 14 December 2017 the Company bought 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 12 855.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.285 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 891 880, representing 6.60 % of the share capital of the Company.

**Dated 15 December 2017**

**Current report No 125**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.12.2017	Buy	4 000	4.2850
14.12.2017	Buy	224	4.2850
14.12.2017	Buy	500	4.2800
14.12.2017	Buy	100	4.2890
14.12.2017	Buy	100	4.2810

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 18 December 2017**  
**Current report No 126**

Sopharma AD hereby informs that on 15 December 2017 the Company bought 130 166 own shares representing 0.0966% of the share capital of the Company, at a total value of 558 151.81 BGN on the Bulgarian Stock Exchange, the average price per share was 4.2880 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 022 046, representing 6.693 % of the share capital of the Company.

**Dated 18 December 2017**  
**Current report No 127**

**NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
15.12.2017	Buy	76	4.2880
15.12.2017	Buy	500	4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 19 December 2017**  
**Current report No 128**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

„Sopharma” AD (the Company) announces that it was notified by „Donev Investments Holding” AD related to Ognian Ivanov Donev, that „Donev Investments Holding” AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.12.2017	Buy	600	4.285
15.12.2017	Buy	335	4.290

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 19 December 2017**  
**Current report No 129**

#### **NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
18.12.2017	Buy	1 455	4.2900
18.12.2017	Buy	45	4.2900
18.12.2017	Buy	500	4.2900
18.12.2017	Buy	500	4.2900
18.12.2017	Buy	1 800	4.2850
18.12.2017	Buy	200	4.2820

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 19 December 2017**  
**Current report No 130**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma” AD (the Company) announces that it was notified by „Elpharma” AD related to Ognian Ivanov Donev, that “Elpharma” AD executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
18.12.2017	Buy	200	4.2850
18.12.2017	Buy	45	4.2900
18.12.2017	Buy	15	4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 20 December 2017**  
**Current report No 131**

## NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
19.12.2017	Buy	300	4.2820
19.12.2017	Buy	108	4.2800
19.12.2017	Buy	400	4.2800
19.12.2017	Buy	192	4.2800
19.12.2017	Buy	22	4.2750
19.12.2017	Buy	450	4.2750
19.12.2017	Buy	28	4.2750
19.12.2017	Buy	500	4.2710
19.12.2017	Buy	1 000	4.2700
19.12.2017	Buy	1 000	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 20 December 2017**



## Current report No 132

### NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
20.12.2017	Buy	543	4.2700
20.12.2017	Buy	3 000	4.2700
20.12.2017	Buy	3 000	4.2700
20.12.2017	Buy	1 457	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 21 December 2017**

**Current report No 133**

Sopharma AD hereby informs that on 15 December 2017 the Company bought 130 166 own shares representing 0.0966% of the share capital of the Company, at a total value of 558 151.81 BGN on the Bulgarian Stock Exchange, the average price per share was 4.2880 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 022 046, representing 6.693 % of the share capital of the Company.

**Dated 21 December 2017**

**Current report No 134**

### NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma" AD (the Company) announces that it was notified by „Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
20.12.2017	Buy	5 000	4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

**Dated 21 December 2017**  
**Current report No 135**

Sopharma AD notifies that on 20 December 2018 Sopharma AD received an approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.891512, meaning that one share of Unipharm AD will be exchanged for 0.891512 shares of Sopharma AD from the treasury shares available to the receiving company.

The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated in the beginning of 2018.

**Dated 28 December 2017**  
**Current report No 136**

**NOTIFICATION OF INSIDERS' TRANSACTIONS**

SOPHARMA AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
21.12.2017	Buy	1 609	4.2700
21.12.2017	Buy	3 391	4.2700
21.12.2017	Buy	121	4.2700
21.12.2017	Buy	199	4.2700
21.12.2017	Buy	1 000	4.2700
21.12.2017	Buy	500	4.2700
21.12.2017	Buy	130	4.2700
22.12.2017	Buy	1 628	4.2700
22.12.2017	Buy	372	4.2700
22.12.2017	Buy	950	4.2830
22.12.2017	Buy	100	4.2830
22.12.2017	Buy	1 490	4.2830
22.12.2017	Buy	510	4.2830

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.